Nanoengineering and Kinetic Transport Analysis of PEGylated CS Niosomes for Controlled Galantamine Delivery

Authors

https://doi.org/10.48313/bic.vi.72

Abstract

The present study investigates the kinetic and transport behavior of polyethylene Glycol–Chitosan (CS) modified Nano-Niosomal carriers for controlled Galantamine Hydrobromide (GH) delivery in Alzheimer’s Disease (AD) therapy. Polyethylene Glycolated (PEGylated)  CS-coated Nano-Niosomes were successfully fabricated using Span 60 and Cholesterol through the thin-film hydration method followed by sonication. The developed nano formulation was physicochemically characterized in terms of particle size, Polydispersity Index (PDI), zeta potential, Encapsulation Efficiency (EE), permeability stability, in vitro drug release behavior, and release Kinetics. The optimized PEG-CS-GH-NIO formulation exhibited a nanoscale particle size of approximately 111.6 nm with a low PDI value of 0.11, confirming the formation of uniformly distributed Nano-Niosomal carriers. The formulation demonstrated a high EE of 98.73% and low permeability during refrigerated storage, indicating enhanced vesicular integrity and effective drug retention. In vitro release studies revealed a biphasic release profile consisting of an initial burst release phase followed by a sustained release phase over 270 min. Mathematical modeling using zero-order, first-order, Higuchi, and Korsmeyer–Peppas equations showed that the zero-order model provided the best correlation coefficient (R² = 0.9973), indicating a nearly concentration-independent controlled release mechanism. Furthermore, the release exponent obtained from the Korsmeyer–Peppas model indicated super-case II transport behavior, suggesting that polymer relaxation, swelling, and structural rearrangement of the PEG-CS  network significantly contributed to galantamine release. Overall, the findings demonstrate that PEGylated CS nano-niosomes represent a promising nanocarrier platform for sustained galantamine delivery and may provide potential advantages for future AD therapeutic strategies.

Keywords:

Niosome, Galantamine hydrobromide, Drug release kinetics, PEGylation, Glycol–Chitosan , Controlled release

References

  1. [1] Gadhave, D. G., Sugandhi, V. V., Jha, S. K., Nangare, S. N., Gupta, G., Singh, S. K., ... & Paudel, K. R. (2024). Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance. Ageing research reviews, 99, 102357. https://doi.org/10.1016/j.arr.2024.102357
  2. [2] Ivanova, M., Panayotova-Ovcharova, L., Nedyalkova-Petkova, D., Petkov, P., Boshev, G., & Vladeva, E. (2025). Galantamine as a potential treatment for peripheral nerve injuries: Emphasis on non-systemic delivery. Future pharmacology, 5(4), 63. https://doi.org/10.3390/futurepharmacol5040063
  3. [3] Suh, G. H., Jung, H. Y., Lee, C. U., Oh, B. H., Bae, J. N., Jung, H. Y., ... & Korean Galantamine Study Group. (2004). A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clinical therapeutics, 26(10), 1608-1618. https://doi.org/10.1016/j.clinthera.2004.10.006
  4. [4] Singh, B., Day, C. M., Abdella, S., & Garg, S. (2024). Alzheimer’s disease current therapies, novel drug delivery systems and future directions for better disease management. Journal of controlled release, 367, 402–424. https://doi.org/10.1016/j.jconrel.2024.01.047
  5. [5] Wang, K., Yang, R., Li, J., Wang, H., Wan, L., & He, J. (2025). Nanocarrier-based targeted drug delivery for Alzheimer’s disease: Addressing neuroinflammation and enhancing clinical translation. Frontiers in pharmacology, 16, 1591438. https://doi.org/10.3389/fphar.2025.1591438
  6. [6] Majumder, J., Taratula, O., & Minko, T. (2019). Nanocarrier-based systems for targeted and site specific therapeutic delivery. Advanced drug delivery reviews, 144, 57–77. https://doi.org/10.1016/j.addr.2019.07.010
  7. [7] Alam, M. A. (2026). Emerging smart nanocarrier based drug delivery systems for cancer therapeutics. Next nanotechnology, 9, 100387. https://doi.org/10.1016/j.nxnano.2026.100387
  8. [8] Kushnazarova, R., Mirgorodskaya, A., Lenina, O., Petrov, K., Lyubina, A., Voloshina, A., ... & Zakharova, L. (2025). Niosomes and tocosomes as promising nanocontainers for the antidiabetic drug repaglinide. Materials today chemistry, 50, 103223. https://doi.org/10.1016/j.mtchem.2025.103223
  9. [9] Kazi, K. M., Mandal, A. S., Biswas, N., Guha, A., Chatterjee, S., Behera, M., & Kuotsu, K. (2010). Niosome: A future of targeted drug delivery systems. Journal of advanced pharmaceutical technology & research, 1(4), 374. https://doi.org/10.4103/0110-5558.76435
  10. [10] Jawale, J. K., & Kashikar, V. S. (2022). Niosomes: A promising nonionic surfactant vesicular system for enhancement of anticancer effect of phytochemicals. International journal of health sciences, 6(S5), 8809–8833.
  11. [11] Saraswathi, T. S., Mothilal, M., & Jaganathan, M. K. (2019). Niosomes as an emerging formulation tool for drug delivery-a review. International journal of applied pharmaceutics, 11(2), 7–15. http://dx.doi.org/10.22159/ijap.2019v11i2.30534
  12. [12] Rangsimawong, W., Opanasopit, P., Rojanarata, T., Duangjit, S., & Ngawhirunpat, T. (2016). Skin transport of hydrophilic compound-loaded PEGylated lipid nanocarriers: Comparative study of liposomes, niosomes, and solid lipid nanoparticles. Biological and pharmaceutical bulletin, 39(8), 1254–1262. https://doi.org/10.1248/bpb.b15-00981
  13. [13] Lei, W., Song, J., Chen, Y., Wang, X., Yang, S., Tan, W., ... & Gao, Z. (2025). Edible polyethylene glycol modified chitosan nanoparticles: Separation and controlled release of tea polyphenols from multiphasic systems. International journal of biological macromolecules, 315, 144375. https://doi.org/10.1016/j.ijbiomac.2025.144375
  14. [14] Baniasad, A., Baei, M. S., & Tala-Tapeh, S. M. (2025). Chitosan-PEGylated niosomes and liposomes as biomacromolecule carriers for Alzheimer’s disease treatment: Galantamine drug delivery carrier. Materials chemistry and physics, 352, 132003. https://doi.org/10.1016/j.matchemphys.2025.132003
  15. [15] Cheng, R., Xu, T., Wang, C., & Gan, C. (2021). The stabilization and antioxidant performances of coenzyme Q10-loaded niosomes coated by PEG and chitosan. Journal of molecular liquids, 325, 115194. https://doi.org/10.1016/j.molliq.2020.115194
  16. [16] Niknejad, K., Sharifzadeh, B. M., & Motallebi, T. T. S. (2018). Synthesis of metformin hydrochloride nanoliposomes: Evaluation of physicochemical characteristics and release kinetics. International journal of nano dimension, 9(3), 298–313. (In Persian). https://www.sid.ir/paper/322408/en
  17. [17] Turkez, H., Oner, S., Yıldırım, O. C., Arslan, M. E., Dimmito, M. P., Kahraman, Ç. Y., ... & Mardinoglu, A. (2025). Synthesis and characterization of memantine-loaded niosomes for enhanced Alzheimer’s disease targeting. Pharmaceutics, 17(2), 267. https://doi.org/10.3390/pharmaceutics17020267
  18. [18] Lu, Q., Lu, P. M., Piao, J. H., Xu, X. L., Chen, J., Zhu, L., & Jiang, J. G. (2014). Preparation and physicochemical characteristics of an allicin nanoliposome and its release behavior. LWT-food science and technology, 57(2), 686-695. https://doi.org/10.1016/j.lwt.2014.01.044
  19. [19] Nanaki, S. G., Spyrou, K., Bekiari, C., Veneti, P., Baroud, T. N., Karouta, N., ... & Bikiaris, D. N. (2020). Hierarchical porous carbon—plla and plga hybrid nanoparticles for intranasal delivery of galantamine for Alzheimer’s disease therapy. Pharmaceutics, 12(3), 227. https://doi.org/10.3390/pharmaceutics12030227
  20. [20] Georgieva, D., Nikolova, D., Vassileva, E., & Kostova, B. (2023). Chitosan-based nanoparticles for targeted nasal galantamine delivery as a promising tool in Alzheimer’s disease therapy. Pharmaceutics, 15(3), 829. https://doi.org/10.3390/pharmaceutics15030829
  21. [21] Tapeh, S. M. T., Baei, M. S., & Keshel, S. H. (2021). Synthesis of thermogel modified with biomaterials as carrier for hUSSCs differentiation into cardiac cells: Physicomechanical and biological assessment. Materials science and engineering: C, 119, 111517. https://doi.org/10.1016/j.msec.2020.111517
  22. [22] Chandrasekhar, P., & Kaliyaperumal, R. (2026). Development of transfersomal buccal patches of galantamine for enhanced bioavailability in Alzheimer’s disease therapy. Journal of applied pharmaceutical research, 14(2), 61–75. https://doi.org/10.69857/joapr.v14i2.1523

Published

2026-09-09

Issue

Vol. 3 No. 3 (2026): Biocompounds

Section

Articles

How to Cite

Baniasad, A. ., & Hoshani, M. . (2026). Nanoengineering and Kinetic Transport Analysis of PEGylated CS Niosomes for Controlled Galantamine Delivery. Biocompounds, 3(3), 162-174. https://doi.org/10.48313/bic.vi.72